State Street Corp Purchases 668,318 Shares of Celcuity Inc. (NASDAQ:CELC)

State Street Corp boosted its stake in shares of Celcuity Inc. (NASDAQ:CELC - Free Report) by 152.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,107,415 shares of the company's stock after buying an additional 668,318 shares during the quarter. State Street Corp owned approximately 2.99% of Celcuity worth $16,512,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Samlyn Capital LLC boosted its holdings in shares of Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company's stock worth $21,735,000 after buying an additional 637,190 shares in the last quarter. Braidwell LP boosted its holdings in Celcuity by 71.2% in the third quarter. Braidwell LP now owns 884,306 shares of the company's stock worth $13,185,000 after acquiring an additional 367,663 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Celcuity by 226.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 221,671 shares of the company's stock worth $3,305,000 after buying an additional 153,712 shares during the last quarter. Driehaus Capital Management LLC increased its position in shares of Celcuity by 62.3% during the second quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company's stock worth $3,351,000 after acquiring an additional 78,525 shares in the last quarter. Finally, Blue Owl Capital Holdings LP bought a new position in Celcuity in the 2nd quarter valued at about $1,065,000. Institutional investors own 63.33% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on CELC. Stifel Nicolaus boosted their price objective on Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a report on Monday, October 7th. Needham & Company LLC reissued a "buy" rating and issued a $23.00 price target on shares of Celcuity in a research report on Friday, November 15th. Finally, HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of Celcuity in a research note on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Celcuity has an average rating of "Buy" and an average price target of $29.17.

Celcuity Stock Performance

Shares of NASDAQ CELC traded up $0.13 during mid-day trading on Wednesday, reaching $12.53. 160,045 shares of the company's stock were exchanged, compared to its average volume of 281,133. The firm has a 50-day moving average price of $13.96 and a two-hundred day moving average price of $15.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The firm has a market capitalization of $465.24 million, a price-to-earnings ratio of -4.80 and a beta of 0.74. Celcuity Inc. has a 52 week low of $11.51 and a 52 week high of $22.19.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.